Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression.

@article{Barragn2008MinimalRD,
  title={Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression.},
  author={Eva Barrag{\'a}n and Juan Carlos Pajuelo and Sandra Ballester and Oscar Fuster and Jos{\'e} D{\'i}az Cervera and F. Moscard{\'o} and Leonor Senent and Esperanza Such and Miguel Angel Sanz and Pascual Bolufer},
  journal={Clinica chimica acta; international journal of clinical chemistry},
  year={2008},
  volume={395 1-2},
  pages={120-3}
}
BACKGROUND Molecular analysis of minimal residual disease is only applicable in acute myeloblastic leukemia (AML) patients with genetic markers (20-30%). This study analyzes the feasibility of the real-time quantitative polymerase chain reaction (RQ-PCR) assay to detect mutant nucleophosmin (NPM1) during follow-up in AML patients. Moreover, we compare the NPM1 results with those of WT1 expression to MRD assessment. METHODS The study includes 97 samples from 24 AML patients with type A NPM1… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

Evaluation of Minimal Residual Disease in Acute Myeloid Leukemia with NPM1 Marker

International journal of hematology-oncology and stem cell research • 2016
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 21 references

Detection and monitoring of minimal residual disease by quantitative real-time PCR.

Clinica chimica acta; international journal of clinical chemistry • 2006

High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2006
View 1 Excerpt

Similar Papers

Loading similar papers…